ACOG Alpha Cognition Inc.

Nasdaq Biological Products, (No Diagnostic Substances) A1 CIK: 0001655923
AI RATING
STRONG_SELL
72% Confidence

Investment Thesis

Alpha Cognition is a pre-commercial stage biotech with unsustainable unit economics: $3.5M revenue against $8.1M operating losses and $11.8M cash burn annually. While the balance sheet is strong with $54.2M cash and zero debt, the company's <5-year cash runway and deeply negative margins (-229% operating margin) indicate a business model not yet proven to generate sustainable returns. Only the 42.2% YoY EPS improvement suggests potential progress, but remains insufficient to offset severe operational losses.

Strengths

  • + Strong balance sheet with $54.2M cash and zero long-term debt
  • + Exceptional liquidity position (12.64x current ratio)
  • + Improving diluted EPS year-over-year (+42.2%), suggesting operational improvements

Risks

  • ! Severe cash burn of $11.8M annually against only $3.5M revenue creates <5 year runway
  • ! Operating margin of -229% indicates business model requires fundamental restructuring before viability
  • ! Pre-commercial stage with no clear path to profitability; 11 Form 4 filings suggest insider uncertainty
  • ! Negative operating and free cash flow indicates company is not yet at inflection point for commercialization

Key Metrics to Watch

Financial Metrics

Revenue
3.5M
Net Income
-6.5M
EPS (Diluted)
$-0.32
Free Cash Flow
-11.8M
Total Assets
69.2M
Cash
54.2M

Profitability Ratios

Gross Margin N/A
Operating Margin -229.1%
Net Margin -183.3%
ROE -11.3%
ROA -9.4%
FCF Margin -333.9%

Balance Sheet & Liquidity

Current Ratio
12.64x
Quick Ratio
11.52x
Debt/Equity
0.00x
Debt/Assets
17.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-16T08:26:29.034985 | Data as of: 2026-03-31 | Powered by Claude AI